secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053553
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance
------------------------------------------------------------

- LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).
- Gross margin expands to 70% from 59% on favorable mix and lower production costs.
- Net loss narrows to $9.1M ($0.25/share) from $13.2M ($0.42); adjusted loss $4.4M ($0.12).
- Raises FY2024 revenue guidance to $132-137M (from $128-135M) and gross margin to 68-70%.
- Cash remains strong at $125.4M, down slightly from $127.2M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017024053553/0000950170-24-053553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017024053553/rxst-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer